Vivos Therapeutics Unveils Pioneering Results for Kids' OSA
Revolutionary Developments in Pediatric OSA Treatment
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a company dedicated to enhancing health through innovative treatment devices, has announced remarkable findings from a substantial clinical trial focusing on pediatric obstructive sleep apnea (OSA). This announcement marks a pivotal moment for children suffering from this increasingly recognized condition.
The company’s proprietary device, the Vivos DNA (Daytime-Nighttime Appliance), has shown to be both safe and effective in treating OSA among children, with the research recently published in an esteemed medical journal. This is not just a minor advancement; it's a breakthrough in addressing a health crisis that is often unnoticed and untreated in the pediatric population.
The Urgency of Pediatric OSA Awareness
Research indicates that nearly 20.4% of children in the U.S. suffer from pediatric OSA, translating to about 10 million youngsters. Strikingly, the majority of these children go undiagnosed, leaving them vulnerable to several serious consequences. OSA is associated with a range of issues, including ADHD, allergies, and even learning challenges like reduced academic performance.
The conventional approach to this ailment has been adenotonsillectomy, a surgical procedure that carries risks and has a limited success rate, helping only 20-40% of those treated. This highlights the need for effective, non-invasive treatments that healthcare providers can offer.
Outstanding Results from the Clinical Trial
The findings from the trial reveal extraordinary improvements for those treated with the Vivos DNA appliance:
- 77% of children experienced significant reductions in OSA severity.
- A staggering 93% of those with severe OSA saw a marked improvement.
- 17% achieved complete resolution of their symptoms, a hopeful statistic for many.
- Airway volume increased by 67.8%, addressing a key measure of success in the treatment.
- Pediatric Sleep Questionnaire results indicated a 31% decrease in symptoms, showing a significant leap forward.
Kirk Huntsman, the Chairman and CEO of Vivos Therapeutics, emphasized the significance of this data. He pointed out that while surgery has long been the primary course of action for OSA, this new evidence supports the Vivos DNA appliance as a safe alternative. Parents can now consider a non-invasive solution before opting for surgical interventions.
Growing Evidence in Favor of Non-Surgical Alternatives
The positive results from this trial contribute to a growing repository of clinical evidence underlining the effectiveness of Vivos’ solutions for pediatric patients. Medical professionals are taking notice, with key contributors to the study invited to present these findings at global medical conferences. For instance, Clete A. Kushida, a leading expert in sleep research, shared exciting insights regarding Vivos technology at a recent congress.
Beyond the Vivos DNA appliance, the company has introduced Vivos Guides, appliances fostering guided jaw growth and aiding in the prevention of OSA development later on. These devices could also alleviate related symptoms such as ADHD behaviors and bedwetting.
- Notably, some studies on Vivos Guides have shown a remarkable ability to eliminate bedwetting in many children within a short period.
- A considerable percentage of children reported a reduction in ADHD symptoms after using Vivos devices.
- Further research verified that many children experienced total symptom resolution in a brief treatment timeframe.
Vivos-trained healthcare providers also implement supportive therapies, including laser treatment for swollen tonsils, complementing the long-term improvements offered by Vivos appliances.
Understanding Vivos Therapeutics
Vivos Therapeutics, Inc. (NASDAQ: VVOS) stands at the forefront of medical technology focused on devising and promoting pioneering diagnostic and treatment strategies for conditions stemming from dental and facial health issues, especially obstructive sleep apnea in both children and adults. Their innovations, particularly the C.A.R.E devices, create new pathways to better health for those suffering from OSA.
Given that OSA affects over a billion people globally, with many unaware they are affected, the importance of Vivos’ work cannot be overstated. Their commitment to addressing the fundamental causes of sleep disordered breathing through advanced, non-invasive technologies could reshape how we treat these conditions.
Founded relatively recently, Vivos aims to revolutionize the approach to these prevalent health issues. The company’s vision is embodied in the proprietary Vivos Method, a clinical approach that emphasizes non-invasive methods to promote proper airway function and health. Through education and collaboration with healthcare providers, Vivos aims to build a brighter, healthier future for millions.
For inquiries regarding media or investors, interested parties can reach out to the contacts provided directly.
Frequently Asked Questions
What does the recent trial show about the Vivos DNA appliance?
The trial demonstrated that the appliance significantly reduces OSA severity in many children, with a noteworthy percentage achieving complete resolution of their symptoms.
How prevalent is pediatric obstructive sleep apnea?
Research suggests that around 10 million children in the U.S. suffer from pediatric OSA, indicating a pressing health concern that requires attention.
What alternatives to surgery does Vivos offer?
Vivos provides non-invasive treatment options through their DNA appliance and specialized guides designed to support healthy growth and development in children.
Who can benefit from Vivos’ treatments?
Children struggling with OSA and related conditions may find relief through Vivos’ innovative appliances offered by trained healthcare providers.
What is the Vivos Method?
The Vivos Method combines non-surgical, non-invasive, and non-pharmaceutical strategies to treat OSA, focusing on long-term health improvement.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.